病原体基因组学在非洲的兴起。

Q2 Pharmacology, Toxicology and Pharmaceutics F1000Research Pub Date : 2024-09-04 eCollection Date: 2024-01-01 DOI:10.12688/f1000research.147114.2
Gerald Mboowa, Francis Kakooza, Moses Egesa, Stephen Tukwasibwe, Stephen Kanyerezi, Ivan Sserwadda, Benson R Kidenya, Jupiter Marina Kabahita, Maria Magdalene Namaganda, Mike Nsubuga, Patricia Nabisubi, Alisen Ayitewala, Grace Kebirungi, Esther Nakafu, Natasha Patience Akwii
{"title":"病原体基因组学在非洲的兴起。","authors":"Gerald Mboowa, Francis Kakooza, Moses Egesa, Stephen Tukwasibwe, Stephen Kanyerezi, Ivan Sserwadda, Benson R Kidenya, Jupiter Marina Kabahita, Maria Magdalene Namaganda, Mike Nsubuga, Patricia Nabisubi, Alisen Ayitewala, Grace Kebirungi, Esther Nakafu, Natasha Patience Akwii","doi":"10.12688/f1000research.147114.2","DOIUrl":null,"url":null,"abstract":"<p><p>The routine genomic surveillance of pathogens in diverse geographical settings and equitable data sharing are critical to inform effective infection control and therapeutic development. The coronavirus disease 2019 (COVID-19) pandemic highlighted the importance of routine genomic surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to detect emerging variants of concern. However, the majority of high-income countries sequenced >0.5% of their COVID-19 cases, unlike low- and middle-income countries. By the end of 2022, many countries around the world had managed to establish capacity for pathogen genomic surveillance. Notably, Beta and Omicron; 2 of the 5 current SARS-CoV-2 variants of concern were first discovered in Africa through an aggressive sequencing campaign led by African scientists. To sustain such infrastructure and expertise beyond this pandemic, other endemic pathogens should leverage this investment. Therefore, countries are establishing multi-pathogen genomic surveillance strategies. Here we provide a catalog of the current landscape of sequenced and publicly shared pathogens in different countries in Africa. Drawing upon our collective knowledge and expertise, we review the ever-evolving challenges and propose innovative recommendations.</p>","PeriodicalId":12260,"journal":{"name":"F1000Research","volume":"13 ","pages":"468"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11512136/pdf/","citationCount":"0","resultStr":"{\"title\":\"The rise of pathogen genomics in Africa.\",\"authors\":\"Gerald Mboowa, Francis Kakooza, Moses Egesa, Stephen Tukwasibwe, Stephen Kanyerezi, Ivan Sserwadda, Benson R Kidenya, Jupiter Marina Kabahita, Maria Magdalene Namaganda, Mike Nsubuga, Patricia Nabisubi, Alisen Ayitewala, Grace Kebirungi, Esther Nakafu, Natasha Patience Akwii\",\"doi\":\"10.12688/f1000research.147114.2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The routine genomic surveillance of pathogens in diverse geographical settings and equitable data sharing are critical to inform effective infection control and therapeutic development. The coronavirus disease 2019 (COVID-19) pandemic highlighted the importance of routine genomic surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to detect emerging variants of concern. However, the majority of high-income countries sequenced >0.5% of their COVID-19 cases, unlike low- and middle-income countries. By the end of 2022, many countries around the world had managed to establish capacity for pathogen genomic surveillance. Notably, Beta and Omicron; 2 of the 5 current SARS-CoV-2 variants of concern were first discovered in Africa through an aggressive sequencing campaign led by African scientists. To sustain such infrastructure and expertise beyond this pandemic, other endemic pathogens should leverage this investment. Therefore, countries are establishing multi-pathogen genomic surveillance strategies. Here we provide a catalog of the current landscape of sequenced and publicly shared pathogens in different countries in Africa. Drawing upon our collective knowledge and expertise, we review the ever-evolving challenges and propose innovative recommendations.</p>\",\"PeriodicalId\":12260,\"journal\":{\"name\":\"F1000Research\",\"volume\":\"13 \",\"pages\":\"468\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11512136/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"F1000Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12688/f1000research.147114.2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"F1000Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12688/f1000research.147114.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

摘要

在不同的地理环境中对病原体进行常规基因组监测和公平的数据共享对于有效的感染控制和治疗开发至关重要。2019 年冠状病毒病(COVID-19)大流行凸显了对严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)进行常规基因组监测以检测新出现的令人担忧的变种的重要性。然而,与中低收入国家不同的是,大多数高收入国家对其 COVID-19 病例的测序率大于 0.5%。到 2022 年底,世界上许多国家已设法建立了病原体基因组监测能力。值得注意的是,非洲科学家领导的积极测序活动首次在非洲发现了 Beta 和 Omicron,它们是目前令人担忧的 5 个 SARS-CoV-2 变体中的 2 个。为了在这次大流行之后继续维持这种基础设施和专业知识,其他流行病原体也应利用这种投资。因此,各国正在建立多病原体基因组监测战略。在此,我们提供了非洲不同国家目前已测序并公开共享的病原体目录。利用我们的集体知识和专长,我们回顾了不断变化的挑战,并提出了创新建议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The rise of pathogen genomics in Africa.

The routine genomic surveillance of pathogens in diverse geographical settings and equitable data sharing are critical to inform effective infection control and therapeutic development. The coronavirus disease 2019 (COVID-19) pandemic highlighted the importance of routine genomic surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to detect emerging variants of concern. However, the majority of high-income countries sequenced >0.5% of their COVID-19 cases, unlike low- and middle-income countries. By the end of 2022, many countries around the world had managed to establish capacity for pathogen genomic surveillance. Notably, Beta and Omicron; 2 of the 5 current SARS-CoV-2 variants of concern were first discovered in Africa through an aggressive sequencing campaign led by African scientists. To sustain such infrastructure and expertise beyond this pandemic, other endemic pathogens should leverage this investment. Therefore, countries are establishing multi-pathogen genomic surveillance strategies. Here we provide a catalog of the current landscape of sequenced and publicly shared pathogens in different countries in Africa. Drawing upon our collective knowledge and expertise, we review the ever-evolving challenges and propose innovative recommendations.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
F1000Research
F1000Research Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
5.00
自引率
0.00%
发文量
1646
审稿时长
1 weeks
期刊介绍: F1000Research publishes articles and other research outputs reporting basic scientific, scholarly, translational and clinical research across the physical and life sciences, engineering, medicine, social sciences and humanities. F1000Research is a scholarly publication platform set up for the scientific, scholarly and medical research community; each article has at least one author who is a qualified researcher, scholar or clinician actively working in their speciality and who has made a key contribution to the article. Articles must be original (not duplications). All research is suitable irrespective of the perceived level of interest or novelty; we welcome confirmatory and negative results, as well as null studies. F1000Research publishes different type of research, including clinical trials, systematic reviews, software tools, method articles, and many others. Reviews and Opinion articles providing a balanced and comprehensive overview of the latest discoveries in a particular field, or presenting a personal perspective on recent developments, are also welcome. See the full list of article types we accept for more information.
期刊最新文献
Household resilience of women migrant worker sellers of Jamu Gendong. Identification of compounds from natural Peruvian sources as potential inhibitors of SARS-CoV-2 Mpro mutations by virtual screening and computational simulations. Clust&See3.0 : clustering, module exploration and annotation. Health care workers hospitalized for COVID-19 in Liberia: who were they, and what were their outcomes? Post-pubertal management of undescended testes from the malignancy risk point of view: a systematic review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1